238 related articles for article (PubMed ID: 21750122)
21. Activation of Toll-like receptors by Burkholderia pseudomallei.
West TE; Ernst RK; Jansson-Hutson MJ; Skerrett SJ
BMC Immunol; 2008 Aug; 9():46. PubMed ID: 18691413
[TBL] [Abstract][Full Text] [Related]
22. TLR activation of the transcription factor XBP1 regulates innate immune responses in macrophages.
Martinon F; Chen X; Lee AH; Glimcher LH
Nat Immunol; 2010 May; 11(5):411-8. PubMed ID: 20351694
[TBL] [Abstract][Full Text] [Related]
23. Francisella novicida LPS has greater immunobiological activity in mice than F. tularensis LPS, and contributes to F. novicida murine pathogenesis.
Kieffer TL; Cowley S; Nano FE; Elkins KL
Microbes Infect; 2003 Apr; 5(5):397-403. PubMed ID: 12737995
[TBL] [Abstract][Full Text] [Related]
24. Prior infection with Type A Francisella tularensis antagonizes the pulmonary transcriptional response to an aerosolized Toll-like receptor 4 agonist.
Walters KA; Olsufka R; Kuestner RE; Wu X; Wang K; Skerrett SJ; Ozinsky A
BMC Genomics; 2015 Oct; 16():874. PubMed ID: 26510639
[TBL] [Abstract][Full Text] [Related]
25. An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain.
Bakshi CS; Malik M; Mahawar M; Kirimanjeswara GS; Hazlett KR; Palmer LE; Furie MB; Singh R; Melendez JA; Sellati TJ; Metzger DW
Vaccine; 2008 Sep; 26(41):5276-88. PubMed ID: 18692537
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of Francisella tularensis phagocytosis using a novel anti-LPS scFv antibody fragment.
Mechaly A; Elia U; Alcalay R; Cohen H; Epstein E; Cohen O; Mazor O
Sci Rep; 2019 Aug; 9(1):11418. PubMed ID: 31388083
[TBL] [Abstract][Full Text] [Related]
27. Oral immunization of mice with the live vaccine strain (LVS) of Francisella tularensis protects mice against respiratory challenge with virulent type A F. tularensis.
KuoLee R; Harris G; Conlan JW; Chen W
Vaccine; 2007 May; 25(19):3781-91. PubMed ID: 17346863
[TBL] [Abstract][Full Text] [Related]
28. Glycogen synthase kinase-3beta (GSK3beta) inhibition suppresses the inflammatory response to Francisella infection and protects against tularemia in mice.
Zhang P; Katz J; Michalek SM
Mol Immunol; 2009 Feb; 46(4):677-87. PubMed ID: 18929413
[TBL] [Abstract][Full Text] [Related]
29. Mast cell TLR2 signaling is crucial for effective killing of Francisella tularensis.
Rodriguez AR; Yu JJ; Guentzel MN; Navara CS; Klose KE; Forsthuber TG; Chambers JP; Berton MT; Arulanandam BP
J Immunol; 2012 Jun; 188(11):5604-11. PubMed ID: 22529298
[TBL] [Abstract][Full Text] [Related]
30. Cellular and humoral immunity are synergistic in protection against types A and B Francisella tularensis.
Sebastian S; Pinkham JT; Lynch JG; Ross RA; Reinap B; Blalock LT; Conlan JW; Kasper DL
Vaccine; 2009 Jan; 27(4):597-605. PubMed ID: 19022323
[TBL] [Abstract][Full Text] [Related]
31. Differential ability of novel attenuated targeted deletion mutants of Francisella tularensis subspecies tularensis strain SCHU S4 to protect mice against aerosol challenge with virulent bacteria: effects of host background and route of immunization.
Conlan JW; Shen H; Golovliov I; Zingmark C; Oyston PC; Chen W; House RV; Sjöstedt A
Vaccine; 2010 Feb; 28(7):1824-31. PubMed ID: 20018266
[TBL] [Abstract][Full Text] [Related]
32. GroEL and lipopolysaccharide from Francisella tularensis live vaccine strain synergistically activate human macrophages.
Noah CE; Malik M; Bublitz DC; Camenares D; Sellati TJ; Benach JL; Furie MB
Infect Immun; 2010 Apr; 78(4):1797-806. PubMed ID: 20123721
[TBL] [Abstract][Full Text] [Related]
33. Inactivated Francisella tularensis live vaccine strain protects against respiratory tularemia by intranasal vaccination in an immunoglobulin A-dependent fashion.
Baron SD; Singh R; Metzger DW
Infect Immun; 2007 May; 75(5):2152-62. PubMed ID: 17296747
[TBL] [Abstract][Full Text] [Related]
34. Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A.
Ray HJ; Cong Y; Murthy AK; Selby DM; Klose KE; Barker JR; Guentzel MN; Arulanandam BP
Clin Vaccine Immunol; 2009 Apr; 16(4):444-52. PubMed ID: 19211773
[TBL] [Abstract][Full Text] [Related]
35. Generation and characterization of hybridoma antibodies for immunotherapy of tularemia.
Lu Z; Roche MI; Hui JH; Unal B; Felgner PL; Gulati S; Madico G; Sharon J
Immunol Lett; 2007 Oct; 112(2):92-103. PubMed ID: 17764754
[TBL] [Abstract][Full Text] [Related]
36. A galU mutant of Francisella tularensis is attenuated for virulence in a murine pulmonary model of tularemia.
Jayakar HR; Parvathareddy J; Fitzpatrick EA; Bina XR; Bina JE; Re F; Emery FD; Miller MA
BMC Microbiol; 2011 Aug; 11():179. PubMed ID: 21819572
[TBL] [Abstract][Full Text] [Related]
37. A Francisella mutant in lipid A carbohydrate modification elicits protective immunity.
Kanistanon D; Hajjar AM; Pelletier MR; Gallagher LA; Kalhorn T; Shaffer SA; Goodlett DR; Rohmer L; Brittnacher MJ; Skerrett SJ; Ernst RK
PLoS Pathog; 2008 Feb; 4(2):e24. PubMed ID: 18266468
[TBL] [Abstract][Full Text] [Related]
38. Production of anti-LPS IgM by B1a B cells depends on IL-1β and is protective against lung infection with Francisella tularensis LVS.
del Barrio L; Sahoo M; Lantier L; Reynolds JM; Ceballos-Olvera I; Re F
PLoS Pathog; 2015 Mar; 11(3):e1004706. PubMed ID: 25768794
[TBL] [Abstract][Full Text] [Related]
39. A Francisella tularensis Schu S4 purine auxotroph is highly attenuated in mice but offers limited protection against homologous intranasal challenge.
Pechous RD; McCarthy TR; Mohapatra NP; Soni S; Penoske RM; Salzman NH; Frank DW; Gunn JS; Zahrt TC
PLoS One; 2008 Jun; 3(6):e2487. PubMed ID: 18575611
[TBL] [Abstract][Full Text] [Related]
40. Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis.
Fulop M; Mastroeni P; Green M; Titball RW
Vaccine; 2001 Aug; 19(31):4465-72. PubMed ID: 11483272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
